Navigation Links
UNC scientists teach enzyme to make synthetic heparin in more varieties
Date:11/25/2008

CHAPEL HILL Scientists at the University of North Carolina at Chapel Hill have learned to customize a key human enzyme responsible for producing heparin, opening the door to a more effective synthetic anticoagulant as well as treatments for other conditions.

Jian Liu, Ph.D., and colleagues at the UNC Eshelman School of Pharmacy have learned to modify the enzyme heparan sulfate 2-O-sulfotransferase, which produces heparin in the human body in addition to other heparin-like molecules. By modifying 2-O-sulfotransferase, researchers will be able to create customized forms of synthetic heparin with different properties.

"Previously it was nearly impossible to change the nature of the heparin generated by the enzyme," said Liu, associate professor in the school's medicinal chemistry and natural products division. "The degree of difficulty was 10-plus. Now it's more like a two or three, which opens the door to the possibility of improving on the natural product."

Heparin is produced naturally by many creatures, including humans. As a drug, it is a common anticoagulant derived mainly from the intestinal lining of pigs. The manufactured form of the substance is most often used during and after procedures such as kidney dialysis, heart bypass surgery, stent implantation, indwelling catheters, and knee and hip replacements to prevent clots from blocking or restricting the flow of blood. The annual worldwide sales of heparin are estimated at $3 billion.

The drug was in the spotlight earlier this year when more than 80 people died and hundreds of others suffered adverse reactions to it, leading to recalls of the drug in countries around the world. Authorities linked the problems to a contaminant in raw natural heparin made from pigs in China. A synthetic version of the drug that can be produced in controlled conditions is key to preventing a recurrence of that tragedy, Liu said.

"The pig stuff has served us well for 50 years and is very inexpensive, but if we cannot control the supply chain, we cannot ensure the safety of the drug," Liu said. "I am working for the day when synthetic heparin can be brewed in large laboratories at a low cost."

There is also interest in heparin as a treatment for small-cell lung cancer, Liu said. Being able to produce customized versions of the heparin molecule using 2-O-sulfotransferase would allow researchers to emphasize the drug's potential anti-cancer properties. Heparin-like structures have also shown potential as treatments for arthritis, asthma and transplant rejection, among other conditions.


'/>"/>

Contact: Patric Lane
patric_lane@unc.edu
919-962-8596
University of North Carolina at Chapel Hill
Source:Eurekalert

Related biology news :

1. Childrens Hospital scientists achieve repair of injured heart muscle in lab tests of stem cells
2. Scientists shed light on evolution of gene regulation
3. Scientists build roach motel for nasty bugs of the bacterial variety
4. Scripps Research scientists shed light on how DNA is unwound so that its code can be read
5. Scientists present moving theory behind bacterial decision-making
6. Penn scientists discover cells reorganize shape to fit the situation
7. Scientists discover 21st century plague
8. Bipolar disorder genes, pathways identified by Indiana University neuroscientists
9. Scripps research scientists identify blood component that turns bacteria virulent
10. Barrow scientists solve 200-year-old scientific debate involving visual illusions
11. Scientists find facial scars increase attractiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2017)... -- According to Acuity Market Intelligence, ongoing concerns ... continue to embrace biometric and digital identification based ... Control (ABC) eGates and 1436 Automated Passport Control ... ports of entry across the globe. Deployments increased ... CAGR of 37%. APC Kiosks reached 75% growth ...
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
Breaking Biology News(10 mins):
(Date:3/1/2017)... and NEW YORK , ... Group (SELLAS or the Company), a late-stage biopharmaceutical ... list of cancer indications, today reported updated positive ... treatment, galinpepimut-S, in multiple myeloma (MM) patients. Consistent ... meaningful clinical benefit among high-risk MM patients, positioning ...
(Date:3/1/2017)... and SHANGHAI , ... a Cork based Biotechnology ... leading preclinical drug discovery Contract Research Organization (CRO), ... partnership to co-market and provide new assay technologies ... HDB will gain access to Luxcel,s state-of-the-art assays ...
(Date:3/1/2017)... ... 01, 2017 , ... At interpack 2017, held in Düsseldorf, ... and quality can help food and pharmaceutical manufacturers improve processes and increase competitiveness ... checkweighing to vision inspection and metal detection – will be on display, as ...
(Date:3/1/2017)... March 1, 2017  Elizabeth Young and Joshua ... the George Washington University,s Health Workforce Speaker series. ... Rosenthal will be speaking on March 9, 2017 ... Washington, DC at 12:00pm. ... invites nationally renowned speakers to examine new workforce configurations, ...
Breaking Biology Technology: